SeaGen Ends March With $456M Cash

Seattle Genetics (NASDAQ: [[ticker:SGEN]]), the developer of targeted cancer drugs, said today in its quarterly financial report that it ended March with $455.9 million of cash and investments in the bank. That’s up from $295 million in cash that it reported heading into this year. The increased cash reserves reflect the addition of $168 million from a stock financing in February, plus revenue from collaborators who are using SeaGen’s technology that links antibodies to toxins that make them more potent against tumors. The company also said the FDA has conditionally accepted its proposal to use Adcetris as the brand name for brentuximab vedotin, its lead drug candidate for Hodgkin’s disease and anaplastic large cell lymphoma.

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.